Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bristol-Myers Squibb (NY: BMY )

60.41 +6.27 (+11.58%)
Streaming Delayed Price Updated: 10:47 AM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,440,459
Open 60.72
Bid (Size) 60.40 (2)
Ask (Size) 60.42 (6)
Prev. Close 54.14
Today's Range 59.53 - 61.08
52wk Range 39.35 - 56.80
Shares Outstanding 2,222,113,553
Dividend Yield 3.77%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for next steps. 
Via Benzinga
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
Via Benzinga

Performance

YTD
+14.50%
+14.50%
1 Month
+15.73%
+15.73%
3 Month
+28.37%
+28.37%
6 Month
+34.07%
+34.07%
1 Year
+20.46%
+20.46%

More News

Read More
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
Via Investor's Business Daily
Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
From Bristol Myers Squibb
Via Business Wire
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
MarketBeat Week in Review – 11/4 - 11/8
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Via Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Via Benzinga
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
Via Investor's Business Daily
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Via Benzinga
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
From Bristol Myers Squibb
Via Business Wire
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Via Benzinga
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance
Via Investor's Business Daily
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
Markets Give Back Gains As Hovering Continues
Via Talk Markets
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Via Benzinga
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
From Bristol Myers Squibb
Via Business Wire
What Lies In Store For Healthcare ETFs In Q3 Earnings?
Via Talk Markets
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.